home / stock / mcrpf / mcrpf news
2023-11-12 06:48:07 ET Summary Stereotaxis was forced to do a human trial for its Magic catheter before it can get CE Mark. This is starting in a few weeks. Stereotaxis will soon submit a PMA for FDA approval of the Magic catheter 180 days after submission. China is set to app...
San Diego-based Kumquat Biosciences announced a $2 billion agreement with a Lilly subsidiary to discover small-molecule drugs that stimulate tumor-specific immune responses in cancer patients. Sirnaomics, a Maryland-Suzhou RNAi therapeutics company, filed to raise $300 million in a Ho...
Elevator Pitch I maintain my "Neutral" rating on Hong Kong-listed medical device manufacturer MicroPort Scientific Corporation ( OTCPK:MCRPF ) [853:HK]. MicroPort Scientific has revised the company's revenue growth guidance for FY2020 downwards as a result of the coronavirus pandemic. Mic...
Elevator Pitch Hong Kong-listed medical device manufacturer MicroPort Scientific Corporation ( MCRPF ) [853:HK] is a long-term play on growing healthcare demand with its dominant coronary stent products and other new products in the pipeline. The stock's 32.7 times consensus forward FY2020 P...
SHANGHAI , Sept. 4, 2018 /PRNewswire/ -- MicroPort Scientific Corporation ("MicroPort®", HK:0853) announced today that the clinical trial results for its Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") which conducted a multi-center, randomized c...
Firehawk® Clinical Data From The TARGET AC European Clinical Trial Has Been Accepted For Publication In The Prestigious Medical Journal The Lancet Canada NewsWire SHANGHAI, Sept. 3, 2018 SHANGHAI , Sept. 3, 2018 /CNW/ -- MicroPort Scientific Corporation ("MicroP...
The following slide deck was published by Microport Scientific Corp. in conjunction with their 2017 Q4 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
Microport Scientific Corp Company Name:
MCRPF Stock Symbol:
OTCMKTS Market:
SHANGHAI , Sept. 4, 2018 /PRNewswire/ -- MicroPort Scientific Corporation ("MicroPort®", HK:0853) announced today that the clinical trial results for its Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") which conducted a multi-center, randomized c...
Firehawk® Clinical Data From The TARGET AC European Clinical Trial Has Been Accepted For Publication In The Prestigious Medical Journal The Lancet Canada NewsWire SHANGHAI, Sept. 3, 2018 SHANGHAI , Sept. 3, 2018 /CNW/ -- MicroPort Scientific Corporation ("MicroP...